David Schenkein, the longtime CEO of Agios Pharmaceuticals, will step aside next year after transforming what was once a high-risk Cambridge, MA-based startup into a public biotech with over 500 employees and two drugs on the market.
Schenkein’s replacement will be Jacqualyn Fouse, former president and chief operating officer of Celgene (NASDAQ: CELG) and a current Agios boardmember. Schenkein will become executive chairman. The handover will take place Feb. 1, the company announced today.
“The CEO role is a 24/7, 365-day-a-year role, and I’m at a stage in my career where I want to think about a different balance in… Read more »
UNDERWRITERS AND PARTNERS